The phase III Southwest Oncology Group (SWOG) S1007 RxPonder trial was designed to evaluate the benefit of chemotherapy added to standard adjuvant endocrine therapy in women with node-positive, HR-positive, HER2-negative early breast cancer with an Oncotype DX® recurrence score of 0-25. Here, ERBB2 is linked to breast carcinoma.